Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Stakeholder Opinions - Restless Legs Syndrome - Novel drugs to prosper as lifecycle management strategies fail (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 19/11/2008
- Report Title: Stakeholder Opinions - Restless Legs Syndrome - Novel drugs to prosper as lifecycle management strategies fail
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 125
Introduction
Restless legs syndrome (RLS) is a neurological condition, which affects 15.5 million medically significant sufferers across the seven major markets (7MM). Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 200506, GlaxoSmithKline and Boehringer Ingelheim pioneered the on-label RLS market, which reached $588m in 2007 across the 7MM.
Scope
*Patient potential including disease definition, etiology, patient segmentation, prevalence, presentation, diagnosis, and treatment guideline review.
*Review of the key unmet needs in the treatment of restless legs syndrome as identified by key opinion leaders for the report.
*Analysis of the RLS market IMS sales data from 2004 to 2007 for major on- and off-label marketed restless legs syndrome drugs.
*Pipeline analysis with detailed profiles for key late-stage drugs: Neupro (rotigotine patch), Nenad (lisuride patch), Solzira (gabapentin enacarbil).
Highlights
Inappropriate pharmacokinetic properties may limit the development of oral extended-release versions of the current oral brands for restless legs syndrome, and prevent off-label prescribing of formulations designed with optimal pharmacokinetics for Parkinson's disease.
Drugs acting with a different mechanism and inducing no augmentation could become beneficial alternatives to current dopamine agonists. Datamonitor expects Solzira to become a leading brand in the future market as specialists and primary care physicians may be more confident to prescribe it to a larger population and particularly to mild patients.
Drugs with new delivery methods could be helpful for RLS patients and prove commercially successful. While formulations with a long duration of action (e.g. UCB's Neupro) may be beneficial for severe patients, treatments with rapid onset of action (e.g. UCB's rotigotine nasal spray) could be used as rescue therapy in moderate-to-severe patients.
Reasons to Purchase
*Quantify the RLS market value in the US, 5EU and Japan and identify the drivers and resistors for RLS treatments.
*Understand key opinion leader (KOL) views on topical issues in the current and future treatment of RLS symptoms.
*Explore the R&D pipeline for RLS and the future directions of the market as identified by interviewed KOLs.
Restless legs syndrome (RLS) is a neurological condition, which affects 15.5 million medically significant sufferers across the seven major markets (7MM). Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 200506, GlaxoSmithKline and Boehringer Ingelheim pioneered the on-label RLS market, which reached $588m in 2007 across the 7MM.
Scope
*Patient potential including disease definition, etiology, patient segmentation, prevalence, presentation, diagnosis, and treatment guideline review.
*Review of the key unmet needs in the treatment of restless legs syndrome as identified by key opinion leaders for the report.
*Analysis of the RLS market IMS sales data from 2004 to 2007 for major on- and off-label marketed restless legs syndrome drugs.
*Pipeline analysis with detailed profiles for key late-stage drugs: Neupro (rotigotine patch), Nenad (lisuride patch), Solzira (gabapentin enacarbil).
Highlights
Inappropriate pharmacokinetic properties may limit the development of oral extended-release versions of the current oral brands for restless legs syndrome, and prevent off-label prescribing of formulations designed with optimal pharmacokinetics for Parkinson's disease.
Drugs acting with a different mechanism and inducing no augmentation could become beneficial alternatives to current dopamine agonists. Datamonitor expects Solzira to become a leading brand in the future market as specialists and primary care physicians may be more confident to prescribe it to a larger population and particularly to mild patients.
Drugs with new delivery methods could be helpful for RLS patients and prove commercially successful. While formulations with a long duration of action (e.g. UCB's Neupro) may be beneficial for severe patients, treatments with rapid onset of action (e.g. UCB's rotigotine nasal spray) could be used as rescue therapy in moderate-to-severe patients.
Reasons to Purchase
*Quantify the RLS market value in the US, 5EU and Japan and identify the drivers and resistors for RLS treatments.
*Understand key opinion leader (KOL) views on topical issues in the current and future treatment of RLS symptoms.
*Explore the R&D pipeline for RLS and the future directions of the market as identified by interviewed KOLs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
